INSIGHT 005
The primary end point of the study is feasibility rate with the secondary end points of incidence and severity of adverse events, objective response rate, progression-free survival, overall survival, and immune response in whole blood and tumor tissue.
Completion date June 30 2024
”EFTi is just not an enhancer of Keytruda
INSIGHT 005The primary end point of the study is feasibility...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
0.020(7.41%) |
Mkt cap ! $421.8M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 29.5¢ | 27.0¢ | $1.138M | 3.985M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 63444 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 65000 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |